Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Graft vs Host Disease

ClinicalTrials.gov lists 1,349 trials for Graft vs Host Disease or a narrower condition beneath it. National Heart, Lung, and Blood Institute (NHLBI) has the most among industry and government lead sponsors, with 29.

MeSH D006086 Immune System Diseases C20 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 138 Phase 1/2 Phase 1/2 128 Phase 2 Phase 2 361 Phase 2/3 Phase 2/3 23 Phase 3 Phase 3 138 Phase 4 Phase 4 74 Not applicable Not applicable 265 Observational Observational 214 Phase 1 Phase 1 138 Phase 1/2 Phase 1/2 128 Phase 2 Phase 2 361 Phase 2/3 Phase 2/3 23 Phase 3 Phase 3 138 Phase 4 Phase 4 74 Not applicable Not applicable 265 Observational Observational 214

Trials per phase

1 more section with rows

693 of the 1,349 trials are tagged with Graft vs Host Disease itself; the rest are tagged with a narrower condition beneath it.

Get the Graft vs Host Disease report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Graft vs Host Disease trials start? (33)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 81

1993: 1 trials (Phase 3 1) 1994: 2 trials (Phase 3 1, Phase 2 1) 1996: 5 trials (Observational 1, Phase 3 2, Phase 2 1, Phase 1/2 1) 1997: 7 trials (Not applicable 2, Phase 3 2, Phase 2 3) 1998: 8 trials (Not applicable 1, Phase 4 1, Phase 2 3, Phase 1 3) 1999: 15 trials (Observational 1, Not applicable 1, Phase 2/3 1, Phase 2 6, Phase 1 6) 2000: 16 trials (Observational 1, Not applicable 3, Phase 3 1, Phase 2/3 1, Phase 2 5, Phase 1/2 3, Phase 1 2) 2001: 13 trials (Observational 1, Not applicable 3, Phase 3 3, Phase 2 4, Phase 1/2 2) 2002: 17 trials (Not applicable 1, Phase 3 4, Phase 2 8, Phase 1/2 3, Phase 1 1) 2003: 31 trials (Observational 3, Not applicable 3, Phase 4 2, Phase 3 3, Phase 2/3 1, Phase 2 10, Phase 1/2 5, Phase 1 4) 2004: 34 trials (Observational 2, Not applicable 5, Phase 4 3, Phase 3 6, Phase 2 11, Phase 1/2 3, Phase 1 4) 2005: 38 trials (Observational 7, Not applicable 6, Phase 4 6, Phase 3 5, Phase 2/3 1, Phase 2 11, Phase 1/2 2) 2006: 39 trials (Observational 4, Not applicable 5, Phase 4 2, Phase 3 7, Phase 2/3 1, Phase 2 15, Phase 1/2 4, Phase 1 1) 2007: 45 trials (Observational 9, Not applicable 2, Phase 4 3, Phase 3 6, Phase 2/3 1, Phase 2 14, Phase 1/2 5, Phase 1 5) 2008: 60 trials (Observational 7, Not applicable 5, Phase 4 6, Phase 3 9, Phase 2/3 1, Phase 2 19, Phase 1/2 3, Phase 1 10) 2009: 52 trials (Observational 10, Not applicable 5, Phase 4 2, Phase 3 6, Phase 2/3 2, Phase 2 15, Phase 1/2 9, Phase 1 3) 2010: 48 trials (Observational 9, Not applicable 8, Phase 4 4, Phase 3 6, Phase 2/3 1, Phase 2 11, Phase 1/2 4, Phase 1 5) 2011: 54 trials (Observational 6, Not applicable 8, Phase 4 2, Phase 3 6, Phase 2/3 1, Phase 2 17, Phase 1/2 8, Phase 1 6) 2012: 58 trials (Observational 13, Not applicable 8, Phase 4 4, Phase 3 9, Phase 2/3 1, Phase 2 11, Phase 1/2 6, Phase 1 6) 2013: 53 trials (Other 1, Observational 5, Not applicable 12, Phase 4 3, Phase 3 8, Phase 2/3 1, Phase 2 13, Phase 1/2 4, Phase 1 6) 2014: 58 trials (Observational 13, Not applicable 9, Phase 4 4, Phase 3 6, Phase 2/3 2, Phase 2 11, Phase 1/2 8, Phase 1 5) 2015: 65 trials (Observational 10, Not applicable 15, Phase 4 3, Phase 3 6, Phase 2/3 2, Phase 2 18, Phase 1/2 3, Phase 1 8) 2016: 57 trials (Observational 4, Not applicable 14, Phase 4 5, Phase 3 2, Phase 2/3 1, Phase 2 20, Phase 1/2 7, Phase 1 4) 2017: 57 trials (Observational 13, Not applicable 12, Phase 4 2, Phase 3 7, Phase 2/3 1, Phase 2 11, Phase 1/2 5, Phase 1 6) 2018: 51 trials (Observational 15, Not applicable 8, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 11, Phase 1/2 4, Phase 1 6) 2019: 46 trials (Observational 7, Not applicable 8, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 11, Phase 1/2 8, Phase 1 5) 2020: 51 trials (Observational 10, Not applicable 10, Phase 3 2, Phase 2 15, Phase 1/2 5, Phase 1 9) 2021: 47 trials (Observational 5, Not applicable 15, Phase 4 4, Phase 3 1, Phase 2 12, Phase 1/2 4, Phase 1 6) 2022: 45 trials (Observational 8, Not applicable 16, Phase 3 4, Phase 2 11, Phase 1/2 3, Phase 1 3) 2023: 51 trials (Observational 18, Not applicable 16, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 2 9, Phase 1/2 2, Phase 1 2) 2024: 64 trials (Observational 11, Not applicable 22, Phase 4 3, Phase 3 3, Phase 2 14, Phase 1/2 6, Phase 1 5) 2025: 81 trials (Observational 14, Not applicable 24, Phase 4 4, Phase 3 6, Phase 2 22, Phase 1/2 5, Phase 1 6)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 62
2025 81
2024 64
2023 51
2022 45
2021 47
2020 51
2019 46
2018 51
2017 57

Showing 10 of 33 earlier years.

Start your 14-day trial Email me all 33 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 79 trials starting in 2026 and about 77 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 128 trials still running at the 2026-10-09 snapshot; registered median of 31 months across 846 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Graft vs Host Disease trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 138
Phase 1/2 128
Phase 2 361
Phase 2/3 23
Phase 3 138
Phase 4 74
Not applicable 265
Observational 214
Expanded access 8

How many Graft vs Host Disease trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 37
Recruiting 154
Enrolling by invitation 10
Active, not recruiting 61
Completed 707

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Graft vs Host Disease trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 29
Novartis Pharmaceuticals 26
National Cancer Institute (NCI) 22
Incyte Corporation 17
Hoffmann-La Roche 12

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Graft vs Host Disease? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 89
Sirolimus 57
Busulfan 45
METHYLPREDNISOLONE 32
RITUXIMAB 25

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
IR Tacrolimus 86
HD- Methotrexate (MTX) 60
SQ Fludarabine 58
Cyclosporine 0.05% 57
Mofetil Mycophenolate 55

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Graft vs Host Disease trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Hospitalizations 2,299 1
Pneumonia 574 82
Death 430 21
Sepsis 259 72
Pyrexia 255 39

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Graft vs Host Disease? (1,799)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft-Versus-Host Disease. Clinical pharmacology and therapeutics 2025 Yes
Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3. Blood advances 2025 Yes
Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025 Yes
The Adverse Event Landscape of Stem Cell Transplant: Evidence for AGVHD Driving Early Transplant Associated Toxicities. Transplantation and cellular therapy 2025 Yes
Recent advances in acute gastrointestinal graft versus host disease (aGvHD): aspects of steroid-resistant disease. Annals of hematology 2025 Yes

Showing 5 of 1,799 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (3)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Graft versus host disease Point prevalence 1-9 / 100 000 Europe Not stated Unspecified
Graft versus host disease Point prevalence 1-9 / 100 000 Europe Not stated Exact
Graft versus host disease Point prevalence 1-9 / 100 000 Europe Not stated Exact

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Graft versus host disease 39812 Exact Orphanet Rare Disease Ontology (ORDO)
Graft versus host disease 39812 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages